Microgenics (US) launches benzodiazepine (BDZ)-abuse assay
This article was originally published in Clinica
Executive Summary
Microgenics (US) has launched a benzodiazepine-abuse assay, controls and calibrators. The Boehringer Mannheim subsidiary says the test has cross-reactivity to a range of benzodiazepine compounds but is not affected by commonly-used OTC pharmaceuticals.